Systematic Review and Meta-Analysis of Endovascular Therapy Effectiveness for Unruptured Saccular Intracranial Aneurysms

Sergio A. Pineda-Castillo¹, Evan R. Jones¹, Keely A. Laurence¹, Lauren R. Thoendel¹, Tanner L. Cabaniss¹, Yan D. Zhao², Bradley N. Bohnstedt³, and Chung-Hao Lee^{1,4*}

¹Biomechanics and Biomaterials Design Laboratory,

School of Aerospace and Mechanical Engineering, The University of Oklahoma, Norman, OK, USA

²Department of Biostatistics and Epidemiology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

³Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, IN, USA

⁴Department of Bioengineering, University of California Riverside, Riverside, CA, USA

^{*} Corresponding Author

Contact Information (author name, e-mail, phone number, full mailing address): C.-H. Lee, <u>ch.lee@ou.edu</u>, +1 (405)325-4842, 865 Asp Ave. Felgar Hall 219C, 865 Asp Ave., Norman, OK 73019, USA

1 ABSTRACT

Background: Currently, endovascular treatment of intracranial aneurysms (ICAs) is limited by low complete occlusion rates. The advent of novel endovascular technology has expanded the applicability of endovascular therapy; however, the superiority of novel embolic devices over the traditional Guglielmi detachable coils (GDCs) is still debated. We performed a systematic review of literature that reported the Raymond-Roy occlusion classifications (RROC) rates of modern endovascular devices to determine their immediate and long-term occlusion effectiveness for the treatment of unruptured saccular ICAs.

<u>Methods:</u> A search was conducted using electronic databases (PUBMED, Cochrane,
 ClinicalTrials.gov, Web of Science). We retrieved studies published between 2000-2022
 reporting immediate and long-term RROC rates of subjects treated with different endovascular
 ICA therapies. We extracted demographic information of the treated patients and their reported
 angiographic RROC rates.

Results: A total of 80 studies from 15 countries were included for data extraction. RROC rates 14 determined from angiogram were obtained for 21,331 patients (72.5% females, pooled mean 15 age: 58.2 (95% CI: 56.8-59.6), harboring 22,791 aneurysms. The most frequent aneurysm 16 locations were the internal carotid artery (46.4%, 95% CI: 41.9%-50.9%), the anterior 17 communicating artery (26.4%, 95% CI: 22.5%-30.8%), the middle cerebral artery (24.5%, 18 95% CI:19.2%-30.8%) and the basilar tip (14.4%, 95% CI:11.3%-18.3%). The RROC rates 19 were analyzed for GDCs, the Woven EndoBridge (WEB), and flow diverters. The immediate 20 complete occlusion (RROC-I) rate was the highest in balloon-assisted coiling (73.9%, 95% CI: 21 65.0%-81.2%) and the lowest in the WEB (27.8%, 95% CI:13.2%-49.2%). The long-term 22 complete occlusion probability was homogenous in all analyzed devices. 23

<u>Conclusions:</u> We observed that the coil-based endovascular therapy provides acceptable rates of complete occlusion, where the balloon-assisted coils provide greater probability of immediate complete occlusion. Out of the analyzed devices, the WEB exhibited the shortest time to achieve >90% probability of long-term complete occlusion (~18 months). Overall, the GDCs remain the *gold standard* for endovascular treatment of unruptured saccular aneurysms.

- 29
- 30 KEYWORDS: endovascular therapy, intracranial aneurysms, flow diverters, Woven
 31 EndoBridge, Guglielmi detachable coils

32 INTRODUCTION

Endovascular treatment of intracranial aneurysms (ICA) emerged in 1991 with the invention of the Guglielmi detachable coils (GDCs).^{1,2} Ever since, endovascular treatment has become the preferred method for ICA therapy due to its minimal invasiveness, lower in-hospital fatalities, and superior clinical outcomes, when compared to the traditional, highly invasive surgical clipping.³⁻⁶ In addition, the coupling of GDCs and other assisting technology, such as balloons and stents, has increased their range of applications and effectiveness, especially for aneurysm with a complex 3D geometry or a high neck-to-sack ratio.⁷

In the last two decades, novel endovascular devices have been designed to expand the 40 application of this minimally invasive method for ICA therapy. The most prominent inventions 41 include bioactive and hydrogel-coated GDCs and flow diverters.^{7,8} For flow diverters, 42 numerous devices have emerged in two categories: (i) extra-saccular: including the p64,⁹ the 43 Pipeline,¹⁰ the Flow Redirection Endoluminal Device (FRED),¹¹ the Surpass,¹² among others; 44 and (ii) intra-saccular flow diverters: such as the Woven EndoBridge (WEB)¹³ and the 45 Contour.¹⁴ The advance of this technology has evolved the application of endovascular therapy 46 for complex aneurysm geometries and even aneurysm locations within the neuro-vasculature. 47

Despite these advancements, current literature has shown that the modern endovascular 48 devices do not demonstrate superior complete occlusion rates than the traditional GDCs for 49 the treatment of unruptured ICAs.¹⁵ Considering that incomplete occlusion drives the 50 recurrence of the treated aneurysm,¹⁶ it is of paramount importance that advances in 51 endovascular therapy are aimed at improving the limited complete occlusion rates of the 52 GDCs. However, meta-analyses aimed to compare the occlusion effectiveness of different 53 endovascular devices are limited by a low sample size (i.e., low number of analyzed studies) 54 and the use of few timepoints for the comparison of long-term occlusion effectiveness. Owing 55 to the great success of novel technologies for endovascular therapy, in this study our objective 56 is to perform a comprehensive assessment of the complete occlusion effectiveness of modern 57 endovascular devices to re-evaluate the notion of the GDCs as the gold standard in 58 endovascular therapy of unruptured saccular ICAs. In addition, we also present a long-term 59 occlusion effectiveness analysis of modern endovascular devices. 60

61 METHODS

62 Literature Search

A systematic literature search was conducted by following the recommendations of Tawfik et 63 al.,¹⁷ the Preferred Reporting Items for the Systematic Reviews and Meta-Analyses (PRISMA) 64 statement,¹⁸ and the Cochrane Handbook for Systematic Reviews of Interventions.¹⁹ Briefly, a 65 search was performed using online databases available at our institution: PubMed, Cochrane, 66 Web of Science, and ClinicalTrials.gov. The search was conducted to obtain both prospective 67 and retrospective studies that were conducted to evaluate the occlusion efficacy of 68 endovascular devices for treating unruptured saccular ICAs, including GDCs, hydrogel-coated 69 coils, WEB, flow diverters, liquid embolic devices, and others. Only peer-reviewed studies 70 published between 2000-2022, with recruitment start date on or after 1999, were included in 71 the screening process. A complete set of queries for the database search can be found in 72 Supplemental Data S1. 73

74 Inclusion/Exclusion of Studies

Screening of the search results was performed using a list of Inclusion/Exclusion (I/E) criteria;
 individual studies not adhering to the I/E criteria were rejected for data collection. Some key
 inclusion criteria (IC) were:

- Reporting of the occlusion rates with Raymond-Roy occlusion classification (RROC) or
 a translatable scale.
- 2. Treating unruptured saccular aneurysms only (in the case of including ruptured aneurysms in study design, occlusion rates must be reported separately per rupture status).
- 3. Reporting of long-term follow-up of ICA occlusion.
- 4. Endovascular treatment must be performed as the first line of treatment for the target
 ICA.
- 86 Exclusion criteria (EC) included:
- 1. Literature reviews.
- 2. Case studies.
- ⁸⁹ 3. Unrelated articles.
- 90 4. Animal studies.
- 5. Studies including trauma-induced, mycotic, pathogen-induced aneurysms.
- 92 6. Studies that reported occlusion rates with no discrimination of saccular and non-93 saccular geometries (i.e., saccular geometries should be reported separately).

A complete list of the I/E criteria can be found in **Supplemental Data S2**. The first stage of screening was performed by three independent reviewers using a spreadsheet containing the title and abstract of the search results after removing duplicates. Then, the second screening was performed by four reviewers by reading the full manuscript. All the studies included after screening were used for data collection.

99 Data Collection

Data collection was performed by two reviewers. Studies were distributed proportionally 100 between reviewers, and data was extracted using a standardized spreadsheet that was 101 previously pilot tested. Data extracted for analysis included: (i) basic study information (first 102 author, country, publication date, sample size), (ii) patient demographics (age and sex), (iii) 103 aneurysm dimensions (largest diameter and neck length), (iv) location in the Circle of Willis 104 (Table 1), and (v) aneurysm occlusion effectiveness results (type of endovascular device, 105 angiographic assessment time, follow-up time, number of aneurysms assessed, and RROC 106 rates). After initial data collection, studies were re-distributed among the reviewers to perform 107 another step of data verification, to confirm correct data extraction. 108

109 Outcomes

The objective of this meta-analysis was to compare the immediate and long-term occlusion rates of modern endovascular devices for treating unruptured ICAs. In addition, the demographic information about ICA size and location on the Circle of Willis was collected and the corresponding meta-averages and meta-proportions were analyzed.

114 Statistical Analysis

Summary statistics reported in individual studies were transformed to obtain the mean \pm standard deviation (SD) of each extracted metric. Proportions, averages, and their respective 95% confidence interval (CI) were pooled across studies using a random-effects mixed model meta-analysis. Heterogeneity was quantified using I^2 . A logistic generalized linear mixed model (LGLMM) was used to compare the time-dependent complete occlusion probability between different endovascular devices. All statistical analyses were performed in R v4.1.2 using the meta-package ²⁰.

Table 1. List of aneurysm locations at the Circle of Willis and their corresponding acronyms.

| Circulation | Artery | Acronym | Portions |
|-------------|--------------------------------------|---------|------------|
| Anterior | Anterior Communicating Artery | ACommA | |
| | Anterior Cerebral Artery | ACA | A1,A2 |
| | Middle Cerebral Artery | MCA | |
| | Internal Carotid Artery | ICaA | |
| | Anterior Choroidal Artery | AChA | |
| | Anteromedial Central Arteries | ACeA | |
| Posterior | Posterior Cerebral Artery | PCA | P1,P2 |
| | Posterior Communicating Artery | PCommA | |
| | Posteromedial Central Arteries | PCeA | |
| | Superior Cerebral Artery | SCA | |
| | Pontine Arteries | PA | |
| | Basilar Artery | BA | Tip, Trunk |
| | Internal Auditory Artery | IAA | |
| | Anterior Spinal Artery | ASA | |
| | Anterior Inferior Cerebellar Artery | AICA | |
| | Posterior Inferior Cerebellar Artery | PICA | |
| | Vertebral Artery | VA | |

123 **RESULTS**

124 Literature Search Results and Screening

Literature search was performed on November 7th, 2022, and yielded 5,227 results, which were included in the screening pipeline presented in **Figure 1**. A total of 80 studies were included for data extraction. A complete list of the included studies is provided in **Supplemental Data 3**.



Figure 1. Flow diagram of the screening of obtained studies. *n* represents the number of studies that were included after each phase of the screening process.

132 Patient and Study Demographics

129

In total, the 80 studies used for data extraction included 21,331 patients from 15 countries that harbored 22,791 aneurysms. See **Supplemental Data S4** for these studies included in data extraction. The pooled female proportion was 72.5% (95% CI: 70.9%-74.2%). The pooled mean patient age was 58.2 (95% CI: 56.8-59.6, **Table 2**). The overall aneurysm maximum diameter average and neck size were 7.2 mm (95% CI: 6.5-7.8 mm) and 4.4 mm (95% CI: 4.1-4.7 mm), respectively (**Table 2**). The pooled proportions of aneurysm location are listed in **Table 3**, whereas the pooled follow-up time was 13.0 months (95% CI: 10.2-15.8 months).

Table 2. Patient demographics and meta-averages of aneurysm dimensions.

| Patient Demographics | n = 21,331 |
|---|--------------------------------|
| Female | 72.5 (70.8-74.1) |
| Age | 58.1 (56.7-59.5) |
| | |
| ICA Geometry | Mean (95% CI) |
| ICA Geometry Average maximum diameter (mm) | Mean (95% Cl) 7.1 (6.5-7.8) |

Table 3. Meta-proportions of ICA anatomic location on the circle of Willis.

| ICA Anatomic Location | % (95% CI) |
|-----------------------|------------------|
| ACommA | 26.4 (22.5-30.8) |
| ACA – A1 | 10.2 (6.1-16.8) |
| ACA – A2 | 7.4 (0.6-52.4) |

| MCA | 24.5 (19.2-30.8) |
|------------|------------------|
| ICaA | 46.4 (41.9-50.9) |
| AChA | 3.4 (3.1-3.8) |
| ACEA | 1.8 (1.6-2.2) |
| PCA – P1 | 2.7 (1.3-5.5) |
| PCA – P2 | 0.8 (0.2-3.1) |
| PCommA | 13.9 (12.2-15.7) |
| PCeA | 1.6 (0.1-19.7) |
| SCA | 4.2 (2.7-6.7) |
| BA – Tip | 14.4 (11.3-18.3) |
| BA – Trunk | 4.7 (2.2-9.8) |
| IAA | 0.7 (0.2-2.3) |
| PICA | 2.9 (1.7-5.0) |
| VA | 3.0 (2.0-4.5) |

Overall, 20,874 ICAs had angiogram-determined occlusion rates reported immediately after treatment or at the earliest follow-up (for flow-diverters only). From this subset, 15,713 (74.9%) were treated with coiling alone, 3,206 (15.3%) with stent-assisted coiling (SAC), 782 (3.72%) with balloon-assisted coiling (BAC), 896 (4.26%) with flow diverters, 270 (1.2%) with the Woven-EndoBridge (WEB), and 158 (0.75%) with other endovascular technologies (i.e., hydrogel-coated coils, Contour Neurovascular system, and Medina).

148 Occlusion Effectiveness

The meta-analysis of aneurysm occlusion effectiveness was performed in three parts: (i) the 149 pooled meta-proportion of the immediate complete IAC occlusion (i.e., RROC-I rates), (ii) the 150 long-term occlusion effectiveness using a LGLMM, and (iii) a comparison of the last available 151 follow-up complete occlusion meta-proportion and the predicted probability of complete 152 occlusion at the average follow-up time based on the LGLMM. All the analyses were 153 performed with the extracted RROC-I rates for Coils (grouped as coiling-alone and assisted-154 coiling techniques), WEB device, and flow diverters. Other devices (hydrogel-coated coils, 155 Contour Neurovascular system) were excluded from the analysis due to a relatively low 156 number of studies available but are included in the overall discussion. 157

158 Immediate Occlusion after Endovascular Treatment

The proportions for RROC-I rates immediately after the endovascular therapy were obtained for each study. A proportion meta-analysis was performed to pool study proportions using a random effects model. A meta-proportion for each individual device is shown in **Table 4**. These proportions represent the global complete occlusion rate obtained in all the studies for each device and its confidence interval. Flow diverters were not analyzed immediately after treatment due to the nature of its mechanism of action, where the target aneurysms become

progressively occluded over time (i.e., no occlusion occurs immediately after treatment but 2-6
 months after the treatment).

167 Long-Term Occlusion Effectiveness of Endovascular Treatment

Binomial LGLMM models were fitted to the occlusion effectiveness data obtained from the 80 168 studies. Three models were obtained for the probability of RROC-I for each individual device 169 categories as a function of angiographic follow-up time: (i) all coiling techniques (i.e., bare 170 coils, SAC, and BAC), (ii) the WEB device, and (iii) flow diverters. The models for other 171 devices were not performed due to a relatively low number of available studies. An individual 172 model for BAC was attempted; however, this was not possible because of the low availability 173 of follow-up time points for this technique. Therefore, only one model for all available coiling 174 data was performed. The corresponding model parameters are summarized in Table 5 and the 175 models fits are shown in Figure 2. In addition, the traditional fixed-effects logistic models 176 (FELM) were compared to the LGLMM to demonstrate how the random effects were induced 177 by individual study variation. 178

Further, the pooled meta-proportions exhibit a higher degree of immediate occlusion for BAC 179 than the other coiling techniques, whereas the WEB exhibited poor immediate occlusion 180 degrees immediately after treatment. On the other hand, the fitted models in Figure 2 181 demonstrate similar complete occlusion behaviors across the different endovascular therapy 182 techniques. The WEB device exhibits a unique behavior, where the initial (FU time = 0 months) 183 occlusion degree approximates the proportion described in **Table 4**, which then increases to 184 similar levels of complete occlusion of coiling and flow diverters. Using the discrete predicted 185 values of the models, we observed that the predicted probability of complete occlusion at 6 186 months for coiling, WEB, and flow diverters was 0.76 (95% CI: 0.67-0.82), 0.53 (95% CI: 0.30-187 0.74), and 0.78 (95% CI: 0.60-0.90). At 11-12 months, the probability increased to 188 0.79 (95% CI: 0.69-0.86) for coils, 0.74 (0.40-0.92) for WEB, and 0.83 (0.65-0.92) for flow 189 diverters. Finally, at the last available FU point RROC-I probability was 0.91 (95% CI: 0.60-190 0.99) at 40 months for coiling, 0.91 (95% CI: 0.41-0.99) at 18 months for WEB, and 0.92 191 (95% CI: 0.37-1.00) for flow diverters. Overall, long-term RROC-I probability was 192 homogeneous across endovascular techniques. 193

Table 4. Pooled meta-proportions and heterogeneity of the RROC-I for modern endovascular
 devices, except flow diverters.

| Device (k studies) | RROC-I Meta-Proportion % (CI 95%) | ľ (%) |
|--------------------|-----------------------------------|-------|
| Coiling (29) | 58.1 (53.4-62.7) | 95.0 |
| SAC(25) | 56.0 (46.0-65.5) | 94.2 |
| BAC (6) | 73.9 (65.0-81.2) | 81.8 |
| WEB (6) | 27.8 (13.2-49.2) | 77.1 |

Table 5. Model parameters for the LGLMM and FELM models of probability of RROC-I as a function of follow-up (FU) time for endovascular therapy techniques. OR: odds ratio.

| Daviaa | Parameter | LGLMM | | | FELM | | |
|----------------|-----------|-------|------------|---------|------|-----------|---------|
| Device | | OR | CI (95%) | p-value | OR | CI | p-value |
| Coiling | Intercept | 2.50 | 1.51-4.15 | <0.001 | 1.15 | 1.12-1.19 | <0.001 |
| Colling | FU time | 1.04 | 0.98-1.09 | 0.199 | 1.03 | 1.03-1.04 | <0.001 |
| | Intercept | 0.37 | 0.08-1.63 | 0.187 | 0.49 | 0.37-0.64 | <0.001 |
| VVED | FU time | 1.20 | 0.98-1.47 | 0.074 | 1.16 | 1.12–1.21 | <0.001 |
| Flow Divertore | Intercept | 2.63 | 0.67-10.32 | 0.165 | 0.77 | 0.65-0.91 | 0.003 |
| Flow Diverters | FU time | 1.05 | 0.92-1.19 | 0.452 | 1.09 | 1.07-1.10 | <0.001 |
| | | | | | | | |



Figure 2. LGLMM model fits for probability of RROC-I as a function of follow-up time for the evaluated endovascular therapy techniques. Grey shading represents CI 95%.

201 DISCUSSION

198

202 Overall Remarks and Occlusion Effectiveness

In this study, 19,751 aneurysms were treated with coil-based techniques in the 22-year span of 203 the included studies. However, coiling exhibited limitations in its early years related to 204 procedural complications, such as aneurysm/parent vessel perforation, mass effect, parent 205 vessel occlusion and/or coil migration.²¹ In addition, the long-term efficacy of coiling is limited 206 by potential coil compaction and/or aneurysm recurrence, thus leading to the need for 207 retreatment of the aneurysm. These limitations led to the development of assisting techniques 208 for coil embolization. For example, the BAC emerged as a safe alternative for ICAs with 209 unfavorable sack-to-neck ratios, and the SEC for more complex geometries (giant, fusiform) 210 with difficult-to-treat locations, such as bifurcation ICAs. Nonetheless, the overall coiling 211 techniques suffer from limitations, including aneurysm recurrence, difficulty to treat aneurysms 212 with tortuous parent vessels, and high re-treatment rates.²² 213

²¹⁴ Based on the limitations of endovascular coil embolization, flow diverters emerged as a great ²¹⁵ alternative for ICA treatment. Flow diverters are similar to stents in terms of fabrication methods and materials (both are tubular wire meshes) but differ in porosity and flexibility. They aim to decouple blood flow between the parent vessel and the aneurysm space, allowing progressive thrombus formation within the aneurysm sac. In addition, the wired mesh acts as a scaffold for neo-endothelization, which can lead to complete parent vessel remodeling.²³ This approach has expanded the application of endovascular therapy to ICA geometries and locations that are not treatable with coiling techniques. Finally, endosaccular flow diverters, like the WEB, have expanded flow diverting technology to bifurcation aneurysms.

- In this study, we aimed to understand the potential of these techniques for the treatment of saccular unruptured aneurysms, a broad ICA category that can be treated with most endovascular approaches. Due to the greater effect of the immediate complete occlusion in recurrence rates and retreatment,^{16,24} understanding the overall RROC-I rate of the most prominent endovascular therapies is of paramount importance for improved therapeutic selection and the development of novel, individualized endovascular technologies.
- The results of this meta-analysis from 22,193 unruptured saccular ICAs showed several key 229 differences and similarities between endovascular devices. We found that the immediate ICA 230 occlusion is improved in the BAC, when compared to other coiling techniques 231 (73.8% [95% CI: 65.0%-81.1%] vs 56.7% [95% CI: 52.5%-60.8%]), as described previously in 232 the literature. These differences contribute to the debate on the differences between coiling 233 techniques, where occlusion rates have been found to be similar for coiling alone, SAC and 234 BAC.²⁵⁻²⁷ In addition, our results validate previous results for RROC-I rates immediately after 235 treatment; we found that RROC-I pooled proportion was 27.7% (95% CI: 13.2%-49.2%), 236 similar to what Asnafi et al. found in their meta-analysis for the same device: 237 27.0% (95% CI: 15.0%-39.0%).²⁸ 238
- In the longer-term post aneurysm embolization, our results indicated that different 239 endovascular therapies provide similar levels of RROC-I rates. In the last available follow-up 240 point, coiling, the WEB, and flow diverters exhibited >90% occlusion (Figure 2). However, the 241 WEB device reached these levels of occlusion in a much shorter time (18 months), while the 242 coiling techniques and flow diverters required at least 40 and 31.5 months, respectively, to 243 achieve the same probability of RROC-I. Quantitatively, this was reflected by a greater odds 244 ratio for the WEB in the GLMM model (Table 5). These findings would be useful to inform 245 current guidelines for method selection for ICA endovascular therapy. 246
- 247 Occlusion Efficacy of Other Devices

In this study, we focused on obtaining the comprehensive information about modern endovascular devices used in studies that fulfilled our I/E criteria. However, not all the included studies could be analyzed in a meta-analysis (e.g., due to a low number of available studies). Specifically, two devices from two separate studies that fulfilled our I/E criteria were not included in this meta-analysis. The devices that were not analyzed were hydrogel-coated coils (HCCs) and the Contour Neurovascular System (CNS).

- The CNS is an intrasaccular flow diverter with a similar mechanism of action as the WEB 254 device. However, their geometries differ from the WEB and make the CNS a separate field of 255 study for this analysis. The CNS is a braided wire mesh that is designed specifically for wide-256 necked bifurcation aneurysms. It has an "upside-down-umbrella" geometry that resembles the 257 original geometry of a bifurcation when deployed in the aneurysm²⁹. The included study by 258 Biondi et al. (2022) ¹⁴ is a retrospective single-arm study where the CNS was tested in 53 259 patients. Complete occlusion using the CNS was 16.7% immediately after treatment, 79.6% at 260 3 months follow-up, and 51.8% at 1 year follow-up. It is not common to see a reduction in 261 complete occlusion when data is available for the whole cohort across follow-up times, and this 262 reduction is not explained in the study discussion. Future research for the CNS should shed 263 more light on the behavior observed in this study. Also, the authors indicate that the patient 264 cohort included their "learning curve" period for the CNS, which can also yield to biased 265 results. Overall, the CNS is a promising device that requires further and prospective research 266 to be included in systematic meta-analysis studies. 267
- On the other hand, the HCCs are an advancement of coil-based technology where the coil is 268 coated with a polymeric sheath, which absorbs water and swells to occupy gaps between coils. 269 This technology was developed to increase packing density of traditional coils. Several trials 270 have been performed to study the advantage of the HCCs over traditional coiling, but no 271 significant differences have been found in immediate complete occlusion rates ^{30,31}. In our 272 meta-analysis, only one study pertinent to the use of the HCCs was accepted for inclusion. 273 Poncyljusz et al.³² performed a single-center controlled randomized trial to compare bare 274 platinum coils (BPCs) and the HCCs, but reported no significant difference in occlusion 275 effectiveness. The HCCs data from this study was not included in any of the meta-analyses 276 due to the only data point for the ICA therapy with HCCs. 277
- 278 Implications for the Development and Translation of Endovascular Devices

Currently, most novel endovascular devices are compared with the GDCs in their pre-clinical 279 and clinical trials. However, with the growth of flow diverting technology (both intra-saccular 280 and extra-saccular), we questioned the *gold standard* status of the GDCs for unruptured 281 aneurysms. Our results demonstrated that immediate occlusion of unruptured saccular ICAs is 282 homogeneous across different coiling technologies, and that other endovascular devices do 283 not offer an advantage over the use of the GDCs for unruptured saccular ICAs. However, the 284 long-term complete occlusion of ICAs is more likely to occur after 18 months of treatment when 285 the WEB devices are used. These findings could guide the clinical decisions on selecting an 286 endovascular device that is better suited for the effectiveness evaluation of novel endovascular 287 embolization system for unruptured ICA therapy. 288

289 Study Limitations

A meta-analysis is understood as the highest form of scientific evidence. However, most meta-290 analyses suffer from a high degree of heterogeneity between the studies used to perform 291 them, in addition to very low availability of data that suffices I/E criteria in the literature. These 292 factors played a significant role in our study. This heterogeneity can be induced by differences 293 in study design, prospective or retrospective data generation and gathering, experience of 294 neurosurgeons with the studied endovascular device, use of internal or centralized 295 assessment of angiographic outcomes, among several other factors. In this study, we aimed at 296 reducing the chances of Type II error by including study-specific variability in the assessment 297 of our data. To do this, all our meta-analyzed metrics (averages and proportions) were 298 calculated using random effects models, which have the great advantage of providing 299 homogeneous weights for all studies in the analysis. In addition, the long-term modeling of 300 RROC-I probability as a function of follow-up time in months was performed using a logistic 301 GLMM, which also accounts for the random effects associated with study-specific variability. 302

Another important limitation in our analysis is related to a low availability of angiographic 303 outcomes in the long-term follow-up (>2 years) of ICAs treated with endovascular devices. This 304 is related to different factors: (i) the WEB became available for clinical use in Europe in 2011 305 and later in other regions; long-term prospective trials have started to become available 306 recently, but more data is expected to be published in the coming decade; (ii) flow diverters 307 can be applied to more ICA geometries than other endovascular devices, including fusiform 308 and dissecting aneurysms; in this study, we aimed at including unruptured saccular aneurysms 309 only, which led to the rejection of a relatively high number of studies that reported angiographic 310

outcomes for all types of geometries together; (iii) we intended to perform analysis of the 311 HCCs as individual endovascular devices; however, it is frequently applied as a "finishing" coil 312 after occupying most of the aneurysm space with bare GDCs. The reporting of this type of 313 procedure is inconsistent across literature, which led our protocol to be designed to only 314 include studies where the HCCs were used as the only type of coil in the aneurysm; (iv) novel 315 devices, including the Medina embolic device,³³ the CNS, the LUNA embolization system³⁴, 316 among other flow diverting devices are still "young" in the endovascular market, and their 317 available data did not fulfill our I/E criteria. 318

319 **Conclusions**

Endovascular therapy for unruptured saccular ICAs has benefited from the emergence of novel 320 technology in the last decade. Intra-saccular and extra-saccular flow diverters are some of the 321 most notable technologies for the treatment of a wide array of ICA geometries, rupture status, 322 and anatomic location. However, the GDCs, and the assisting technology used to improve its 323 applicability, remains a great tool for endovascular embolization of unruptured saccular ICAs. 324 The immediate RROC rates for the GDCs are yet to be improved and future developments in 325 endovascular ICA therapeutics should aim to address this long-standing limitation to reduce 326 aneurysm recurrence. Nevertheless, the WEB device shows great promise in reducing periods 327 for progressive complete occlusion, as demonstrated in this meta-analysis. 328

329 AVAILABILITY OF DATA

³³⁰ Data not included in the Supplemental Data will be available upon request to the authors, ³³¹ including templates for data collection, a list of rejected studies after screening, raw extracted ³³² data from the included studies and scripts from R Studio for data analysis.

333 AUTHOR CONTRIBUTION

S.A.P.-C. contributed to conceptualization, study design, screening of studies at all stages of 334 the systematic search, data extraction, statistical design, and analysis, and writing the original 335 draft. E.R.J contributed as a reviewer in the screening of studies for the systematic search and 336 data extraction. K.A.L, L.R.T. and T.L.C. assisted in the screening of studies for the systematic 337 search. Y.D.Z. contributed to study design and statistical analysis. B.N.B. contributed to 338 conceptualization and manuscript editing. C.-H.L. contributed to conceptualization, 339 supervision, manuscript editing, and funding acquisition. All authors read and approved the 340 final article. 341

342 FUNDING INFORMATION

We acknowledge funding support from the National Institutes of Health (NIH) Grant R01 HL159475, OCAST Health Research Program (HR-18-002), and the OSCTR Pilot Grant Program. S.A.P.-C was supported in part by the University of Oklahoma Graduate College Alumni Fellowship.

347 DISCLOSURE STATEMENT

³⁴⁸ The authors declare no competing financial interests.

349 **REFERENCES**

- Guglielmi, G., Viñuela, F., Dion, J., *et al.* Electrothrombosis of saccular aneurysms via
 endovascular approach: Part 2: Preliminary clinical experience. Journal of Neurosurgery
 75, 8, 1991. doi: 10.3171/jns.1991.75.1.0008
- Guglielmi, G., Vinuela, F., Sepetka, I., *et al.* Electrothrombosis of saccular aneurysms via
 endovascular approach. Part 1: Electrochemical basis, technique, and experimental
 results. Journal of Neurosurgery **75**, 1, 1991. doi: 10.3171/jns.1991.75.1.0001
- Claiborne, J.S., Wilson, C.B., Halbach, V.V., *et al.* Endovascular and surgical treatment of unruptured cerebral aneurysms: Comparison of risks. Annals of Neurology **48**, 11, 2000.
 doi: 10.1002/1531-8249(200007)48:1<11::aid-ana4>3.3.co;2-m
- Molyneux, A.J., Kerr, R.S., Yu, L.-M., *et al.* International subarachnoid aneurysm trial (isat)
 of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured
 intracranial aneurysms: A randomised comparison of effects on survival, dependency,
 seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet **366**, 809, 2005. doi:
 10.1053/jscd.2002.130390
- 5. Kang, X.K., Guo, S.F., Lei, Y., *et al.* Endovascular coiling versus surgical clipping for the
 treatment of unruptured cerebral aneurysms: Direct comparison of procedure-related
 complications. Medicine (Baltimore) **99**, e19654, 2020. doi:
 10.1097/md.00000000019654
- Chai, C.L., Jeon, J.P., Tsai, Y.-H., *et al.* Endovascular intervention versus surgery in
 ruptured intracranial aneurysms in equipoise. Stroke **51**, 1703, 2020. doi:
 doi:10.1161/STROKEAHA.120.028798
- T. Laurent, D., Lucke-Wold, B., Leary, O., *et al.* The evolution of endovascular therapy for
 intracranial aneurysms: Historical perspective and next frontiers. Neuroscience Insights
 17, 26331055221117560, 2022. doi: 10.1177/26331055221117560
- White, P.M., Lewis, S.C., Gholkar, A., *et al.* Hydrogel-coated coils versus bare platinum
 coils for the endovascular treatment of intracranial aneurysms (HELPS): A randomised
 controlled trial. Lancet **377**, 1655, 2011. doi: 10.1016/S0140-6736(11)60408-X
- 9. Alain, B., Marta Aguilar, P., Hans, H., *et al.* Diversion-p64: Results from an international,
 prospective, multicenter, single-arm post-market study to assess the safety and

| 379 | | effectiveness of the p64 flow modulation device. Journal of NeuroInterventional Surgery |
|-----|-----|--|
| 380 | | 14 , 898, 2022. doi: 10.1136/neurintsurg-2021-017809 |
| 381 | 10. | Tibor, B., David, F.K., Isil, S., et al. Pipeline for uncoilable or failed aneurysms: Results |
| 382 | | from a multicenter clinical trial. Radiology, 2013. doi: 10.1148/radiol.13120099 |
| 383 | 11. | Piano, M., Valvassori, L., Lozupone, E., et al. Fred Italian registry: A multicenter |
| 384 | | experience with the flow re-direction endoluminal device for intracranial aneurysms. |
| 385 | | Journal of Neurosurgery, 1, 2019. doi: 10.3171/2019.1.JNS183005 |
| 386 | 12. | Issa, R., Al-Homedi, Z., Syed, D.H., et al. Surpass evolve flow diverter for the treatment of |
| 387 | | intracranial aneurysm: A systematic review. Brain Sciences 12 , 810, 2022. doi: |
| 388 | | 10.3390/brainsci12060810 |
| 389 | 13. | van Rooij, S., Sprengers, M., Peluso, J., et al. A systematic review and meta-analysis of |
| 390 | | woven endobridge single layer for treatment of intracranial aneurysms. Interventional |
| 391 | | Neuroradiology 26 , 455, 2020. doi: 10.1177/1591019920904421 |
| 392 | 14. | Biondi, A., Primikiris, P., Vitale, G., et al. Endosaccular flow disruption with the contour |
| 393 | | neurovascular system: Angiographic and clinical results in a single-center study of 60 |
| 394 | | unruptured intracranial aneurysms. Journal of NeuroInterventional Surgery, 2022. doi: |
| 395 | | 10.1136/jnis-2022-019271 |
| 396 | 15. | Pineda-Castillo, S.A., Stiles, A.M., Bohnstedt, B.N., et al. Shape memory polymer-based |
| 397 | | endovascular devices: Design criteria and future perspective. Polymers 14 , 2526, 2022. |
| 398 | | doi: 10.3390/polym14132526 |
| 399 | 16. | Sadato, A., Hayakawa, M., Adachi, K., et al. Large residual volume, not low packing |
| 400 | | density, is the most influential risk factor for recanalization after coil embolization of |
| 401 | | cerebral aneurysms. PLoS ONE 11 , e0155062, 2016. doi: 10.1371/journal.pone.0155062 |
| 402 | 17. | Tawfik, G.M., Dila, K.A.S., Mohamed, M.Y.F., et al. A step by step guide for conducting a |
| 403 | | systematic review and meta-analysis with simulation data. Tropical Medicine and Health |
| 404 | | 47 , 46, 2019. doi: 10.1186/s41182-019-0165-6 |
| 405 | 18. | Moher, D., Liberati, A., Tetzlaff, J., et al. Preferred reporting items for systematic reviews |
| 406 | | and meta-analyses: The PRISMA statement. Journal of Clinical Epidemiology 62 , 1006, |
| 407 | | 2009. doi: 10.1016/j.jclinepi.2009.06.005 |
| | | |

- McKenzie, J.E., Brennan, S.E., Ryan, R.E., *et al.* Defining the criteria for including studies
 and how they will be grouped for the synthesis. Cochrane Handbook for Systematic
 Reviews of Interventions2019. pp. 33. doi: 10.1002/9781119536604.ch3
- 20. Balduzzi, S., Rücker, G., and Schwarzer, G. How to perform a meta-analysis with R: A
 practical tutorial. Evidence Based Mental Health 22, 153, 2019. doi: 10.1136/ebmental2019-300117
- Murayama, Y., Nien, Y.L., Duckwiler, G., *et al.* Guglielmi detachable coil embolization of
 cerebral aneurysms: 11 years' experience. Journal of Neurosurgery **98**, 959, 2003. doi:
 10.3171/jns.2003.98.5.0959
- 22. Lee, K.S., Zhang, J.J.Y., Nguyen, V., et al. The evolution of intracranial aneurysm
- treatment techniques and future directions. Neurosurgical Review 45, 1, 2022. doi:
 10.1007/s10143-021-01543-z
- Ravindran, K., Salem, M.M., Alturki, A.Y., *et al.* Endothelialization following flow diversion
 for intracranial aneurysms: A systematic review. American Journal of Neuroradiology 40,
 295, 2019. doi: 10.3174/ajnr.A5955
- 423 24. Grunwald, I.Q., Papanagiotou, P., Struffert, T., *et al.* Recanalization after endovascular
 424 treatment of intracerebral aneurysms. Neuroradiology **49**, 41, 2007. doi: 10.1007/s00234 425 006-0153-5
- Vivanco-Suarez, J., Wallace, A.N., Dandapat, S., *et al.* Stent-assisted coiling versus
 balloon-assisted coiling for the treatment of ruptured wide-necked aneurysms: A 2-center
 experience. Stroke: Vascular and Interventional Neurology 3, e000456, 2023. doi:
 doi:10.1161/SVIN.122.000456
- Waldeck, S., Chapot, R., von Falck, C., *et al.* A comparative evaluation of standard and
 balloon-assisted coiling of intracranial aneurysms based on neurophysiological monitoring.
 Journal of Clinical Medicine **11**, 677, 2022. doi: 10.3390/jcm11030677
- 27. Chalouhi, N., Starke, R.M., Koltz, M.T., *et al.* Stent-assisted coiling versus balloon
 remodeling of wide-neck aneurysms: Comparison of angiographic outcomes. American
 Journal of Neuroradiology **34**, 1987, 2013. doi: 10.3174/ajnr.A3538
- 436 28. Asnafi, S., Rouchaud, A., Pierot, L., *et al.* Efficacy and safety of the woven endobridge
 437 (WEB) device for the treatment of intracranial aneurysms: A systematic review and meta438 analysis. American Journal of Neuroradiology **37**, 2287, 2016. doi: 10.3174/ajnr.A4900

- Akhunbay-Fudge, C.Y., Deniz, K., Tyagi, A.K., *et al.* Endovascular treatment of wide necked intracranial aneurysms using the novel contour neurovascular system: A single center safety and feasibility study. Journal of NeuroInterventional Surgery **12**, 987, 2020.
 doi: 10.1136/neurintsurg-2019-015628
- 30. Xue, T., Chen, Z., Lin, W., *et al.* Hydrogel coils versus bare platinum coils for the
 endovascular treatment of intracranial aneurysms: A meta-analysis of randomized
 controlled trials. BMC Neurology **18**, 2018. doi: 10.1186/s12883-018-1171-8
- 31. Taschner, C.A., Chapot, R., Costalat, V., *et al.* Second-generation hydrogel coils for the
 endovascular treatment of intracranial aneurysms: A randomized controlled trial. Stroke
 448 49, 667, 2018. doi: 10.1161/STROKEAHA.117.018707
- 32. Poncyljusz, W., Zarzycki, A., Zwarzany, Ł., *et al.* Bare platinum coils vs. Hydrocoil in the
 treatment of unruptured intracranial aneurysms: A single center randomized controlled
 study. European Journal of Radiology **84**, 261, 2015. doi: 10.1016/j.ejrad.2014.11.002
- Aguilar Perez, M., Bhogal, P., Martinez Moreno, R., *et al.* The medina embolic device:
 Early clinical experience from a single center. Journal of Neurointerventional Surgery 9,
 77, 2017. doi: 10.1136/neurintsurg-2016-012539
- 34. Piotin, M., Biondi, A., Sourour, N., *et al.* The luna aneurysm embolization system for
 intracranial aneurysm treatment: Short-term, mid-term and long-term clinical and
 angiographic results. Journal of Neurointerventional Surgery **10**, e34, 2018. doi:
 10.1136/neurintsurg-2018-013767